{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:46:02Z","timestamp":1792608362938,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0210123, JP24fk0210113, JP24fk0210111, JP24fk0210104, JP24fk0210126"],"award-info":[{"award-number":["JP24fk0210123, JP24fk0210113, JP24fk0210111, JP24fk0210104, JP24fk0210126"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0210123, JP24fk0210113, JP24fk0210111, JP24fk0210104, JP24fk0210126"],"award-info":[{"award-number":["JP24fk0210123, JP24fk0210113, JP24fk0210111, JP24fk0210104, JP24fk0210126"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0210123, JP24fk0210113, JP24fk0210111, JP24fk0210104, JP24fk0210126"],"award-info":[{"award-number":["JP24fk0210123, JP24fk0210113, JP24fk0210111, JP24fk0210104, JP24fk0210126"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23HC2001, 23HC2002, 23HC2003"],"award-info":[{"award-number":["23HC2001, 23HC2002, 23HC2003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23HC2001, 23HC2002, 23HC2003"],"award-info":[{"award-number":["23HC2001, 23HC2002, 23HC2003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s10637-024-01470-y","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T08:03:45Z","timestamp":1725005025000},"page":"559-565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma"],"prefix":"10.1007","volume":"42","author":[{"given":"Nami","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshie","family":"Mashiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Doisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Marusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Kobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Nonogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohito","family":"Urawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namiki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"1470_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"1470_CR2","doi-asserted-by":"publisher","first-page":"155744","DOI":"10.1016\/j.metabol.2023.155744","volume":"152","author":"DJH Tan","year":"2024","unstructured":"Tan DJH, Ng CH, Muthiah M et al (2024) Rising global burden of cancer attributable to high BMI from 2010 to 2019. Metabolism 152:155744","journal-title":"Metabolism"},{"key":"1470_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R (2021) Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 18:223\u2013238","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1470_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/hepr.13839","volume":"53","author":"S Kirino","year":"2023","unstructured":"Kirino S, Tamaki N, Kurosaki M et al (2023) Alanine aminotransferase levels as therapeutic targets after nucleotide\/nucleoside analog therapy in patient with chronic hepatitis B. Hepatol Res 53:35\u201342","journal-title":"Hepatol Res"},{"key":"1470_CR5","doi-asserted-by":"publisher","first-page":"e3349","DOI":"10.1093\/cid\/ciaa1307","volume":"73","author":"N Tamaki","year":"2021","unstructured":"Tamaki N, Kurosaki M, Yasui Y et al (2021) Change in fibrosis 4 index as predictor of high risk of incident hepatocellular carcinoma after eradication of hepatitis C virus. Clin Infect Dis 73:e3349\u2013e3354","journal-title":"Clin Infect Dis"},{"key":"1470_CR6","doi-asserted-by":"publisher","unstructured":"Enomoto H, Akuta N, Hikita H et al (2024) Etiological changes of liver cirrhosis and hepatocellular carcinoma-complicated liver cirrhosis in Japan: updated nationwide survey from 2018 to 2021. Hepatol Res. https:\/\/doi.org\/10.1111\/hepr.14047","DOI":"10.1111\/hepr.14047"},{"key":"1470_CR7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1007\/s10637-022-01303-w","volume":"40","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Tada T, Kurosaki M et al (2022) Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab. Invest New Drugs 40:1290\u20131297","journal-title":"Invest New Drugs"},{"key":"1470_CR8","doi-asserted-by":"publisher","first-page":"e0231828","DOI":"10.1371\/journal.pone.0231828","volume":"15","author":"S Kirino","year":"2020","unstructured":"Kirino S, Tsuchiya K, Kurosaki M et al (2020) Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. PLoS ONE 15:e0231828","journal-title":"PLoS ONE"},{"key":"1470_CR9","doi-asserted-by":"publisher","unstructured":"Wang W, Tsuchiya K, Kurosaki M et al (2019) Sorafenib-regorafenib sequential therapy in japanese patients with unresectable hepatocellular carcinoma-relative dose intensity and post-regorafenib therapies in real world practice. Cancers (Basel) 11. https:\/\/doi.org\/10.3390\/cancers11101517","DOI":"10.3390\/cancers11101517"},{"key":"1470_CR10","doi-asserted-by":"publisher","unstructured":"Yasui Y, Kurosaki M, Tsuchiya K et al (2022) Real-world data on ramucirumab therapy including patients who experienced two or more systemic treatments: a multicenter study. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14122975","DOI":"10.3390\/cancers14122975"},{"key":"1470_CR11","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905","journal-title":"N Engl J Med"},{"key":"1470_CR12","doi-asserted-by":"publisher","first-page":"EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1:EVIDoa2100070","journal-title":"NEJM Evid"},{"key":"1470_CR13","doi-asserted-by":"publisher","unstructured":"Rose MG, Kennedy EB, Abou-Alfa GK et al (2024) Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update clinical insights. JCO Oncol Pract:Op2400189. https:\/\/doi.org\/10.1200\/OP.24.00189","DOI":"10.1200\/OP.24.00189"},{"key":"1470_CR14","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M et al (2023) AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78:1922\u20131965","journal-title":"Hepatology"},{"key":"1470_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hepr.13892","volume":"53","author":"K Hasegawa","year":"2023","unstructured":"Hasegawa K, Takemura N, Yamashita T et al (2023) Clinical Practice Guidelines for Hepatocellular Carcinoma: the Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res 53:383\u2013390","journal-title":"Hepatol Res"},{"key":"1470_CR16","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"Llovet JM, Lencioni R (2020) mRECIST for HCC: performance and novel refinements. J Hepatol 72:288\u2013306","journal-title":"J Hepatol"},{"key":"1470_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"1470_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lungcan.2019.12.017","volume":"140","author":"M Giaj Levra","year":"2020","unstructured":"Giaj Levra M, Cott\u00e9 FE, Corre R et al (2020) Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer 140:99\u2013106","journal-title":"Lung Cancer"},{"key":"1470_CR19","doi-asserted-by":"publisher","first-page":"100620","DOI":"10.1016\/j.jhepr.2022.100620","volume":"5","author":"B Scheiner","year":"2023","unstructured":"Scheiner B, Roessler D, Phen S et al (2023) Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma. JHEP Rep 5:100620","journal-title":"JHEP Rep"},{"key":"1470_CR20","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.21.00079","volume":"39","author":"DJ Olson","year":"2021","unstructured":"Olson DJ, Eroglu Z, Brockstein B et al (2021) Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma. J Clin Oncol 39:2647\u20132655","journal-title":"J Clin Oncol"},{"key":"1470_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","volume":"402","author":"SK Pal","year":"2023","unstructured":"Pal SK, Albiges L, Tomczak P et al (2023) Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 402:185\u2013195","journal-title":"Lancet"},{"key":"1470_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA et al (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16:275\u2013287","journal-title":"Nat Rev Cancer"},{"key":"1470_CR23","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","volume":"18","author":"J Borst","year":"2018","unstructured":"Borst J, Ahrends T, B\u0105ba\u0142a N et al (2018) CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 18:635\u2013647","journal-title":"Nat Rev Immunol"},{"key":"1470_CR24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375\u2013384","journal-title":"Lancet Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01470-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01470-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01470-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T09:11:06Z","timestamp":1733562666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01470-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01470-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Masayuki Kurosaki and Kaoru Tsuchiya received lecture fee from AstraZeneca and Chugai. Other authors have no conflicts of interest to declare related to the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}